. home.aspx



First LSCD patient in UK receives Chiesi’s Holoclar

November 04, 2019 / Pharmaceutical Technology

The first patient, funded by the UK’s National Health Service (NHS), has received treatment with Chiesi’s stem-cell-based therapy Holoclar for limbal stem cell deficiency (LSCD) caused by chemical eye burns. The patient received treatment at Newcastle upon Tyne Hospitals NHS Foundation Trust. LSCD is a rare eye disorder, which could result in chronic pain, photophobia, burning, inflammation, stromal scarring, corneal neovascularisation and even blindness. Chiesi’s Holoclar is a form of advanced therapy called a tissue-engineered product, made of cells obtained from the patient’s healthy limbus during a biopsy. The extracted cells are sent to the manufacturing facility at Holostem Terapie Avanzate in Italy to be prepared and grown in a culture to generate a layer of healthy tissue. After a minimum of 50 days, the healthy tissue layer is transported back to the treating hospital for implantation into the damaged eye to repair the damaged corneal surface. The Natio...